Systemic Therapy for Patients With Advanced Human Epidermal ...
This study adds to our understanding of T- DXd for treatment of HER2- low breast cancer. Received March 25, 2022; accepted September 13, 2022.
HER2-positive Breast Cancer The clinician's perspectiveSo far, T is routinely used for patients with HER2-positive metastatic breast cancer, showing good efficacy and tolerability given as monotherapy as well as in ... Therapeutic strategies for HER2-positive breast cancer with central ...With the recognition of T-DXd as the preferred second-line treatment regimen of HER2-positive ABC, and with ongoing clinical trials investigating its role ... Management of patients with HER2-positive metastatic breast ...Risk factors for CHF: low LVEF, age, obesity, hypertension. ? LVEF is mandatory before initiation of trastuzumab and during treatment. ESO-ESMO EEBR Masterclass ...
Autres Cours:
